The antitumor immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70/SEA complex protein vaccine following different administration routes.
Our previous study showed that nanoemulsion-encapsulated MAGE1-HSP70/SEA (MHS) complex protein vaccine elicited MAGE-1 specific immune response and antitumor effects against MAGE-1-expressing tumor and nanoemulsion is a useful vehicle with possible important implications for cancer biotherapy. The purpose of this study was to compare the immune responses induced by nanoemulsion-encapsulated MAGE1-HSP70 and SEA as NE(MHS) vaccine following different administration routes and to find out the new and effective immune routes. Nanoemulsion vaccine was prepared using magnetic ultrasound methods. C57BL/6 mice were immunized with NE(MHS) via po., i.v., s.c. or i.p., besides mice s.c. injected with PBS or NE(-) as control. The cellular immunocompetence was detected by ELISpot assay and LDH release assay. The therapeutic and tumor challenge assay were also examined. The results showed that the immune responses against MAGE-1 expressing murine tumors elicited by NE(MHS) via 4 different routes were approximately similar and were all stronger than that elicited by PBS or NE(-), suggesting that this novel nanoemulsion carrier can exert potent antitumor immunity against antigens encapsulated in it. Especially, the present results indicated that nanoemulsion vaccine adapted to administration via different routes including peroral, and may have broader applications in the future.
Ge
Wei
W
Department of Pathology, State Key Laboratory of Cancer Biology, Xijing Hospital, Fourth Military Medical University, Xi'an, Shaanxi Province 710032, P.R. China.
Hu
Pei-Zhen
PZ
Huang
Yang
Y
Wang
Xiao-Ming
XM
Zhang
Xiu-Min
XM
Sun
Yu-Jing
YJ
Li
Zeng-Shan
ZS
Si
Shao-Yan
SY
Sui
Yan-Fang
YF
D000818:Animals; D000951:Antigens, Neoplasm / Q000008:administration & dosage / Q000276:immunology*; D019496:Cancer Vaccines / Q000008:administration & dosage / Q000276:immunology*; D003602:Cytotoxicity, Immunologic / Q000187:drug effects; D016503:Drug Delivery Systems / Q000379:methods*; D004655:Emulsions; D004768:Enterotoxins / Q000008:administration & dosage / Q000276:immunology*; D004797:Enzyme-Linked Immunosorbent Assay; D018840:HSP70 Heat-Shock Proteins / Q000008:administration & dosage / Q000276:immunology*; D007371:Interferon-gamma / Q000187:drug effects; D008546:Melanoma, Experimental / Q000276:immunology / Q000628:therapy; D051379:Mice; D008810:Mice, Inbred C57BL; D036103:Nanotechnology / Q000379:methods; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000276:immunology
D000951:Antigens, Neoplasm; D019496:Cancer Vaccines; D004655:Emulsions; D004768:Enterotoxins; D018840:HSP70 Heat-Shock Proteins; D011993:Recombinant Fusion Proteins; C026066:enterotoxin A, Staphylococcal; D007371:Interferon-gamma